BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia

Rhea-AI Summary

BioCardia (Nasdaq: BCDA) announced CEO Peter Altman's participation in two upcoming symposia focusing on therapeutic developments in heart failure and acute respiratory distress syndrome. The first event, on July 14, 2022, at 10:00 a.m. ET, is hosted by Maxim Group LLC, featuring discussions with other players in the heart failure space. The second symposium, on July 15, 2022, at 9:10 a.m., will showcase BioCardia's research on NK1R+ MSC in treating acute respiratory distress syndrome. Further details can be found on BioCardia's website.

SUNNYVALE, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- BioCardia^®, Inc. [Nasdaq: BCDA], Sunnyvale, Calif. – BioCardia^®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Company’s CEO Peter Altman has been invited to participate at two upcoming therapeutic development symposia.

BioCardia will participate in the Late-Stage Advancements in Heart Failure Therapeutics and Management, presented by Maxim Group LLC and hosted by M-Vest, on Thursday, July 14th, 2022, at 10:00 a.m. ET.    MVEST will host a panel discussion on heart failure with several late-stage players in the space; BioCardia, Inc. (BCDA), Mesoblast Limited (MESO), Recardio Inc. (private), and scPharmaceuticals Inc. (SCPH).    This conference will be live on M-Vest. To attend, potential participants should sign up to become an M-Vest member.  Click Here to Reserve your seat 

BioCardia will also present at the 2^nd Annual Acute Respiratory Distress Syndrome Drug Development Symposium, an industry-specific event for respiratory drug developers on Friday July 15^th, 2022, at 9:10am entitled Exploring the IV NK1R+ MSC in Acute Respiratory Distress Syndrome. BioCardia’s presentation will be made available on the Company’s website soon after the presentation. Details on the conference are here: https://ards-summit.com/program/full-event-guide/.

ABOUT BIOCARDIA

BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP™ autologous and NK1R+ allogeneic cell therapies are the Company’s biotherapeutic platforms that enable four product candidates in development. The CardiAMP Cell Therapy Heart Failure Trial investigational product has been granted Breakthrough designation by the FDA, has CMS reimbursement, and is supported financially by the Maryland Stem Cell Research Fund. The CardiAMP Chronic Myocardial Ischemia Trial also has CMS Reimbursement.  For more information visit: www.BioCardia.com.

Media Contact:
Anne Laluc, Marketing
Email: alaluc@BioCardia.com
Phone: 650-226-0120

Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120

FAQ

What events is BioCardia participating in July 2022?

BioCardia will participate in two events: a heart failure symposium on July 14 and a respiratory distress symposium on July 15.

When is BioCardia presenting at the heart failure symposium?

BioCardia's presentation at the heart failure symposium is on July 14, 2022, at 10:00 a.m. ET.

What will BioCardia present at the respiratory distress symposium?

At the respiratory distress symposium on July 15, 2022, BioCardia will present on IV NK1R+ MSC in acute respiratory distress syndrome.

Where can I find more information about BioCardia's events?

More information about BioCardia's events can be found on their official website.

What is the significance of the FDA Breakthrough designation for BioCardia?

The FDA Breakthrough designation for BioCardia's CardiAMP product accelerates development and review processes, supporting its clinical trial efforts.